US Cancer Generics Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“US Cancer Generics Market Outlook 2022” report gives comprehensive insight on the various indicators and trend analysis related to the emergence and integration of cancer generics drugs in mainstream pharmaceutical market in US. The report analyzes various clinical and non-clinical parameters responsible for the growth on cancer generics drugs in recent years. The introduction of generics has resulted in saving of billions of dollars for various stake holders involved US cancer drug market. It is expected that total savings from generics in cancer therapy (in treatment & post treatment) will surpass US$ 30 Billion by 2022 and will further give the required thrust to adoption of generics drugs in cancer therapy as compare to prescribed branded drugs.
Even though most of the attention and spending in the oncology segment in the US has been focused on the remarkable scientific inventions of the newer targeted drugs but the overburdening of the economic high cost of cancer drugs has made US to follow up the line of generics. Certainly, after the existence of Hatch-Waxman Act, the entries of generic products were acceptable between the Americans.
The beneficial aspects of generic regimens are already well established, as the delivery of equal therapeutic efficacy in low price is the principal aim of cancer generics. The cost for patented oncological drugs and the generic drugs have wide gap which is getting shorter with the emerging patent cliff for cancer drugs in US and the arrival of the cancer generics era.
Concerning the cost, indeed cancer generics provide an exceptional solution towards high cost, yet the scenario is different for the Americans. However, in US cancer generics cost much higher in contrary to the other nations, reason being is the no negotiation mode of government in the pharmaceutical sector. The prices paid for generics in US are many fold higher than developing countries like India and China.
Certainly, among the developed nations the usage and prescription of generics is quite higher depicting the greater medical needs due to overburden of massive diseases and cancer is one of them. The demand for cancer generics is so high that the trend has created a shortage landscape. It is a part of the problem of the scarcity of generics across all medical specialties, but its oncology is particularly vulnerable. The reason of the shortages is multi-factorial but is largely economic and is due to the lack of incentives to produce generics.
“US Cancer Generics Market Outlook 2022” report highlights:
“US Cancer Generics Market Outlook 2022” report gives comprehensive insight on the various indicators and trend analysis related to the emergence and integration of cancer generics drugs in mainstream pharmaceutical market in US. The report analyzes various clinical and non-clinical parameters responsible for the growth on cancer generics drugs in recent years. The introduction of generics has resulted in saving of billions of dollars for various stake holders involved US cancer drug market. It is expected that total savings from generics in cancer therapy (in treatment & post treatment) will surpass US$ 30 Billion by 2022 and will further give the required thrust to adoption of generics drugs in cancer therapy as compare to prescribed branded drugs.
Even though most of the attention and spending in the oncology segment in the US has been focused on the remarkable scientific inventions of the newer targeted drugs but the overburdening of the economic high cost of cancer drugs has made US to follow up the line of generics. Certainly, after the existence of Hatch-Waxman Act, the entries of generic products were acceptable between the Americans.
The beneficial aspects of generic regimens are already well established, as the delivery of equal therapeutic efficacy in low price is the principal aim of cancer generics. The cost for patented oncological drugs and the generic drugs have wide gap which is getting shorter with the emerging patent cliff for cancer drugs in US and the arrival of the cancer generics era.
Concerning the cost, indeed cancer generics provide an exceptional solution towards high cost, yet the scenario is different for the Americans. However, in US cancer generics cost much higher in contrary to the other nations, reason being is the no negotiation mode of government in the pharmaceutical sector. The prices paid for generics in US are many fold higher than developing countries like India and China.
Certainly, among the developed nations the usage and prescription of generics is quite higher depicting the greater medical needs due to overburden of massive diseases and cancer is one of them. The demand for cancer generics is so high that the trend has created a shortage landscape. It is a part of the problem of the scarcity of generics across all medical specialties, but its oncology is particularly vulnerable. The reason of the shortages is multi-factorial but is largely economic and is due to the lack of incentives to produce generics.
“US Cancer Generics Market Outlook 2022” report highlights:
- Introduction to Cancer Generics
- US Generic Drugs Legislature
- US Health Insurance Scenario & Cancer
- Aspects of Branded & Non-Branded Generics
- US Cancer Generics Market Overview
1. CANCER GENERICS: A MODEST REGIMEN
1.1 Introduction to Cancer Generics
1.2 Why There Exist is Need for Generic Forms?
1.3 Supremacy of Cancer Generic Drugs
1.3.1 Cost
1.3.2 Quality & Safety
1.3.3 Large Number of Manufacturer
1.3.4 Approved by FDA
1.3.5 Concerns in Cancer Generic Medication
2. US GENERIC DRUGS LEGISLATURE
2.1 Hatch-Waxman Act, 1984
2.2 The Generic Drugs Chronological Disgrace
3. TRAIL TOWARDS PATENTING OF CANCER GENERIC DRUGS
3.1 US Generic Pharmaceutical Regulation
3.2 Patenting Wars of Cancer Generics in US
4. ECONOMIC BURDEN OF PRESCRIPTION DRUGS IN US
4.1 High Cost of Cancer Drugs
4.2 Healthcare Savings by Virtue of Generics
5. CANCER GENERIC DRUGS: STILL OVERPRICED IN US MARKET
5.1 Innovation is Meaningless if Nobody can Afford It
5.2 Why US Contends More in Generics?
6. US HEALTH INSURANCE SCENARIO & CANCER
6.1 Provisions for Cancer Drug Coverage
6.2 Private Health Insurance Options
6.3 Government Funded Insurance
7. ASPECTS OF BRANDED & NON-BRANDED GENERICS
7.1 Debut of Authorized Generics in Market
7.2 Anti-Authorized Generic Legislation
8. GENERICS IN ONCOLOGY WORLD
8.1 Anti-Cancer Targeted Therapy Drugs
8.2 Status of Generics in Monoclonal Antibodies
8.3 Crusade of Small Molecule Inhibitor towards Generics
9. FDA APPROVED ANTI-CANCER GENERICS IN US
9.1 Taxotere (Generic Docetaxel)
9.2 Imatinib (Generic Glivec)
9.3 Sorafinib ( Generics Nexavar)
10. US CANCER GENERICS MARKET OVERVIEW
10.1 US Cancer Generics Market Introduction
10.2 Europe Generics Market Contrary to US
10.3 Asia Generics Market Contrary to US
11. CANCER GENERICS DRUG MARKET DYNAMICS
11.1 Accelerative Parameters
11.1.1 Expiration of Patents
11.1.2 Unaffordability of Cancer Drugs
11.1.3 Cost Containment by Government
11.1.4 Generic Drug User Fee Amendments (2012)
11.1.5 High Cancer Risk & Aging Population of US
11.2 Pitfalls Confronted by Generic Industry
12. US CANCER GENERICS MARKET FUTURE PROSPECT
1.1 Introduction to Cancer Generics
1.2 Why There Exist is Need for Generic Forms?
1.3 Supremacy of Cancer Generic Drugs
1.3.1 Cost
1.3.2 Quality & Safety
1.3.3 Large Number of Manufacturer
1.3.4 Approved by FDA
1.3.5 Concerns in Cancer Generic Medication
2. US GENERIC DRUGS LEGISLATURE
2.1 Hatch-Waxman Act, 1984
2.2 The Generic Drugs Chronological Disgrace
3. TRAIL TOWARDS PATENTING OF CANCER GENERIC DRUGS
3.1 US Generic Pharmaceutical Regulation
3.2 Patenting Wars of Cancer Generics in US
4. ECONOMIC BURDEN OF PRESCRIPTION DRUGS IN US
4.1 High Cost of Cancer Drugs
4.2 Healthcare Savings by Virtue of Generics
5. CANCER GENERIC DRUGS: STILL OVERPRICED IN US MARKET
5.1 Innovation is Meaningless if Nobody can Afford It
5.2 Why US Contends More in Generics?
6. US HEALTH INSURANCE SCENARIO & CANCER
6.1 Provisions for Cancer Drug Coverage
6.2 Private Health Insurance Options
6.3 Government Funded Insurance
7. ASPECTS OF BRANDED & NON-BRANDED GENERICS
7.1 Debut of Authorized Generics in Market
7.2 Anti-Authorized Generic Legislation
8. GENERICS IN ONCOLOGY WORLD
8.1 Anti-Cancer Targeted Therapy Drugs
8.2 Status of Generics in Monoclonal Antibodies
8.3 Crusade of Small Molecule Inhibitor towards Generics
9. FDA APPROVED ANTI-CANCER GENERICS IN US
9.1 Taxotere (Generic Docetaxel)
9.2 Imatinib (Generic Glivec)
9.3 Sorafinib ( Generics Nexavar)
10. US CANCER GENERICS MARKET OVERVIEW
10.1 US Cancer Generics Market Introduction
10.2 Europe Generics Market Contrary to US
10.3 Asia Generics Market Contrary to US
11. CANCER GENERICS DRUG MARKET DYNAMICS
11.1 Accelerative Parameters
11.1.1 Expiration of Patents
11.1.2 Unaffordability of Cancer Drugs
11.1.3 Cost Containment by Government
11.1.4 Generic Drug User Fee Amendments (2012)
11.1.5 High Cancer Risk & Aging Population of US
11.2 Pitfalls Confronted by Generic Industry
12. US CANCER GENERICS MARKET FUTURE PROSPECT
LIST OF FIGURES
Figure 1-1: US - Savings through Generic Drug usage (US$ Billion), 2010-2015
Figure 1-2: Zofran- Price of Branded & Generic Pill (US$)
Figure 1-3: Illustration of Pros & Cons of Generic Drugs
Figure 2-1: Interests of Brand drug & Generic Drug Industry over Hatch-Waxman Act
Figure 3-1: Major Exclusivity under the NDA Statutory Requirements
Figure 3-2: Demonstration of Bringing Generic Drug into Market
Figure 3-3: US - FDA Rules for Generics Production
Figure 4-1: Branded V/S Generic Prescription Drug Revenues (2005-2015)
Figure 4-2: US – Expected Cost Savings through Generics in Cancer Therapy (US$ Billion), 2016-2022
Figure 4-3: US - Potential Cost Saving Across Biologics in
Figure 5-1: US - Representation of Generic Cost of Gleevac
Figure 6-1: Distribution of Medicare Savings in FY2016 Budget
Figure 6-2: Cost Sharing of Generic Drug in Medicare Part D Coverage Gap (%), 2015-2020
Figure 6-3: Various Medicare Beneficiaries Provided by US Government
Figure 6-4: US - Share of Medicare & Self Payment for Generics Drug (%)
Figure 7-1: Illustration of the Profits Earned During the 180-Day Exclusivity
Figure 7-2: Strategies for Launching Authorized Generics in Market
Figure 8-1: US - Proportion of Branded & Generic Drug Revenues (%), 2010-2015
Figure 8-2: FDA Approved Monoclonal Antibodies in Cancer Therapeutics
Figure 8-3: Development Cost of Generics v/s Biosimilar
Figure 9-1: Cost Comparison of Gleevac in Branded & Generic Versions
Figure 9-2: Naxawar Price Difference in Generic & Branded Version
Figure 10-1: Global - Top Generics Manufacturers Based on Revenues (US$ Billion), 2015
Figure 10-2: US – Generics Drug Market Opportunity (US$ Billion). 2016-2022
Figure 10-3: US - Savings through Generic Drug usage in (US$ Billion), 2017-2022
Figure 10-4: US - Share of Leading Generic Companies
Figure 11-1: Major Accelerative Parameters for the Growth of Generic Market
Figure 11-2: Current Challenges Faced by Generic Pharmaceutical
Figure 1-1: US - Savings through Generic Drug usage (US$ Billion), 2010-2015
Figure 1-2: Zofran- Price of Branded & Generic Pill (US$)
Figure 1-3: Illustration of Pros & Cons of Generic Drugs
Figure 2-1: Interests of Brand drug & Generic Drug Industry over Hatch-Waxman Act
Figure 3-1: Major Exclusivity under the NDA Statutory Requirements
Figure 3-2: Demonstration of Bringing Generic Drug into Market
Figure 3-3: US - FDA Rules for Generics Production
Figure 4-1: Branded V/S Generic Prescription Drug Revenues (2005-2015)
Figure 4-2: US – Expected Cost Savings through Generics in Cancer Therapy (US$ Billion), 2016-2022
Figure 4-3: US - Potential Cost Saving Across Biologics in
Figure 5-1: US - Representation of Generic Cost of Gleevac
Figure 6-1: Distribution of Medicare Savings in FY2016 Budget
Figure 6-2: Cost Sharing of Generic Drug in Medicare Part D Coverage Gap (%), 2015-2020
Figure 6-3: Various Medicare Beneficiaries Provided by US Government
Figure 6-4: US - Share of Medicare & Self Payment for Generics Drug (%)
Figure 7-1: Illustration of the Profits Earned During the 180-Day Exclusivity
Figure 7-2: Strategies for Launching Authorized Generics in Market
Figure 8-1: US - Proportion of Branded & Generic Drug Revenues (%), 2010-2015
Figure 8-2: FDA Approved Monoclonal Antibodies in Cancer Therapeutics
Figure 8-3: Development Cost of Generics v/s Biosimilar
Figure 9-1: Cost Comparison of Gleevac in Branded & Generic Versions
Figure 9-2: Naxawar Price Difference in Generic & Branded Version
Figure 10-1: Global - Top Generics Manufacturers Based on Revenues (US$ Billion), 2015
Figure 10-2: US – Generics Drug Market Opportunity (US$ Billion). 2016-2022
Figure 10-3: US - Savings through Generic Drug usage in (US$ Billion), 2017-2022
Figure 10-4: US - Share of Leading Generic Companies
Figure 11-1: Major Accelerative Parameters for the Growth of Generic Market
Figure 11-2: Current Challenges Faced by Generic Pharmaceutical
